NASDAQ:ADMP Adamis Pharmaceuticals (ADMP) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free ADMP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.77▼$3.9952-Week Range N/AVolume119,800 shsAverage Volume811,695 shsMarket Capitalization$7.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Adamis Pharmaceuticals alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Adamis Pharmaceuticals Stock (NASDAQ:ADMP)Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Read More Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him ADMP Stock News HeadlinesNovember 8, 2023 | morningstar.comDMK Pharmaceuticals Corp DMKSeptember 7, 2023 | msn.comAdamis changes name to DMK Pharmaceuticals, ticker to DMKApril 24, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.September 7, 2023 | finance.yahoo.comAdamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic FocusAugust 21, 2023 | finanznachrichten.deAdamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 21, 2023 | finance.yahoo.comAdamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 4, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Closing of $8.0 Million Public OfferingAugust 2, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Pricing of $8.0 Million Public OfferingApril 24, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.August 1, 2023 | msn.comAdamis Pharmaceuticals Stock Soars To More Than Double - What's Going On?August 1, 2023 | msn.comAdamis stock soars as high as 480% amid asset sale, drug study newsJuly 28, 2023 | marketwatch.comAdamis Pharma to Fund Clinical Study with University of Leiden Opioid ExpertJuly 28, 2023 | finance.yahoo.comAdamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid ExpertJune 26, 2023 | benzinga.comAdamis Pharmaceuticals Announces NIH Grant Funding For Treatment Of Alcohol Use Disorder, Size Not DisclosedJune 26, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use DisorderJune 22, 2023 | finance.yahoo.comAdamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose PreventionJune 4, 2023 | fool.comAdamis Pharmaceuticals (NASDAQ: ADMP)May 31, 2023 | benzinga.comAdamis Pharmaceuticals CEO Awarded $210K Worth of Stock OptionsMay 31, 2023 | benzinga.comBoard Member at Adamis Pharmaceuticals Acquires Company Stock Options Worth 25,720 SharesMay 26, 2023 | finanznachrichten.deAdamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Announces Closing of the Merger with DMK PharmaceuticalsMay 25, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Closing of the Merger with DMK PharmaceuticalsMay 21, 2023 | seekingalpha.comAdamis Pharma slips 19% on plans for reverse stock slipMay 19, 2023 | finanznachrichten.deAdamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Announces Reverse Stock SplitMay 19, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Reverse Stock SplitMay 16, 2023 | finance.yahoo.comQ1 2023 Adamis Pharmaceuticals Corp Earnings CallMay 15, 2023 | finance.yahoo.comAdamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 8, 2023 | finance.yahoo.comAdamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate UpdateSee More Headlines Receive ADMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/31/2022Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolNASDAQ:ADMP CUSIPN/A CIK887247 Webwww.adamispharmaceuticals.com Phone(858) 997-2400FaxN/AEmployees11Year Founded2006Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,480,000.00 Net Margins-502.73% Pretax Margin-471.80% Return on Equity-420.53% Return on Assets-256.87% Debt Debt-to-Equity RatioN/A Current Ratio0.23 Quick Ratio0.19 Sales & Book Value Annual Sales$4.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.26) per share Price / BookN/AMiscellaneous Outstanding Shares9,360,000Free Float9,237,000Market Cap$7.26 million OptionableOptionable Beta1.27 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. David J. Marguglio (Age 53)Co-Founder, Interim CFO. Pres & COO Comp: $526.35kDr. Ebrahim Versi M.D. (Age 70)Ph.D., CEO & Chair of the Board Ms. Jennifer C. SuskiSr. Director of MarketingMr. Eddie Wabern Glover (Age 73)Chief Exec. Officer of US Compounding Inc Mr. Robert B. Rothermel (Age 79)Consultant Key CompetitorsSonoma PharmaceuticalsNASDAQ:SNOAVivos TherapeuticsNASDAQ:VVOSGraybug VisionNASDAQ:GRAYKinetaNASDAQ:KAeFFECTOR TherapeuticsNASDAQ:EFTRView All Competitors ADMP Stock Analysis - Frequently Asked Questions How were Adamis Pharmaceuticals' earnings last quarter? Adamis Pharmaceuticals Co. (NASDAQ:ADMP) announced its earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative net margin of 502.73% and a negative trailing twelve-month return on equity of 420.53%. During the same period last year, the firm earned ($11.20) earnings per share. When did Adamis Pharmaceuticals' stock split? Adamis Pharmaceuticals's stock reverse split on the morning of Monday, May 22nd 2023. The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Adamis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK). This page (NASDAQ:ADMP) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsFed launches fourth dollar overhaulStansberry ResearchThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adamis Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
